Scarica l'app Stockscreener
0.1027
0.29%
-0.0003
Propanc Biopharma Inc Borsa (PPCB) Ultime notizie
Propanc Biopharma announces up to $100M strategic financing from Hexstone Capital - MSN
[EFFECT] Propanc Biopharma, Inc. SEC Filing - Stock Titan
Trending Industry Today: Propanc Biopharma Leads Gains In ETH-Holding Companies Stocks - Moomoo
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB - The Joplin Globe
The selling point was good, but there's still a loss. This money can't be used to average down. - Moomoo
Propanc Biopharma Incfiles to offer resale of up to 15 million shares of common stock by selling stockholderSEC filing - marketscreener.com
Propanc Biopharma (PPCB) files S-1 for 15M-share resale from Series C preferred - Stock Titan
PPCB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Propanc Biopharma (PPCB) approves restricted grants, reverse split 1:10–1:30 - Stock Titan
Propanc Biopharma, Inc. (PPCB) - Minichart
What should investors watch in Propanc Biopharma (PPCB) Stock | Price at $0.10, Down 3.30%Risk Reward Ratio - Xã Châu Thành
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - BioSpace
Propanc extends 17-year Spain research tie to study aging and cancer - Stock Titan
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer - GlobeNewswire
Propanc Biopharma (PPCB) approves 33M shares and 1:10–1:30 reverse split - Stock Titan
Propanc & Fyonibio Launch Assay for Phase 1b Human Study - The Clinical Trial Vanguard
PPCB Should I Buy - Intellectia AI
Propanc Biopharma (PPCB) Stock Analysis Report | Financials & Insights - Benzinga España
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy - Bitget
13% survival in pancreatic cancer; Propanc therapy hits >85% tumor inhibition - Stock Titan
Propanc Biopharma signs contract for Phase 1b cancer trial assay By Investing.com - Investing.com Canada
Propanc Biopharma contracts FyoniBio for drug assay development By Investing.com - Investing.com South Africa
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study - Bitget
Propanc Biopharma contracts FyoniBio for drug assay development - Investing.com
Propanc Biopharma signs contract for Phase 1b cancer trial assay - Investing.com
Propanc Biopharma Executes Service Agreement with FyoniBio - GlobeNewswire
Propanc Biopharma | 424B3: Prospectus - Moomoo
Propanc Biopharma's lead asset PRP shows >85% tumor growth inhibition in preclinical pancreatic models - marketscreener.com
Propanc Biopharma highlights potential of lead asset PRP - TipRanks
Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models - TradingView
Deadliest cancer stuck at 13% survival: new PRP therapy targets spread - Stock Titan
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement By Investing.com - Investing.com South Africa
Propanc Biopharma Announces Board Change and New Appointment - TipRanks
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement - Investing.com Nigeria
Propanc Biopharma (PPCB) adds oncology expert Ralf Brandt to board as Kenyon retires - Stock Titan
Propanc Biopharma | EFFECT: Others - Moomoo
Propanc Biopharma files four new patent applications for cancer treatment By Investing.com - Investing.com South Africa
Propanc Biopharma files four new patent applications for cancer treatment - Investing.com
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results - The Manila Times
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Certain Warrants of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026. - marketscreener.com
0.39%
4.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):